Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Capital Expenditures for 6 consecutive years, with $141979.0 as the latest value for Q1 2023.

  • Quarterly Capital Expenditures fell 93.9% to $141979.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Mar 2023, down 149.87% year-over-year, with the annual reading at $57607.0 for FY2022, 97.33% down from the prior year.
  • Capital Expenditures for Q1 2023 was $141979.0 at Marker Therapeutics, up from -$24691.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.5 million in Q2 2020, with the low at -$2.3 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $236041.8, with a median of $66170.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures soared 1233.58% in 2020, then tumbled 3741.79% in 2022.
  • Over 5 years, Capital Expenditures stood at -$223126.0 in 2019, then crashed by 220.28% to -$714619.0 in 2020, then soared by 392.51% to $2.1 million in 2021, then plummeted by 101.18% to -$24691.0 in 2022, then skyrocketed by 675.02% to $141979.0 in 2023.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $141979.0, -$24691.0, and $66170.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.